These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38044448)

  • 21. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
    Bletsa E; Filippas-Dekouan S; Kostara C; Dafopoulos P; Dimou A; Pappa E; Chasapi S; Spyroulias G; Koutsovasilis A; Bairaktari E; Ferrannini E; Tsimihodimos V
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1269-1283. PubMed ID: 33592103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.
    Lazzaroni E; Lunati ME; Montefusco L; Pastore I; Chebat E; Cimino V; Morpurgo PS; Muratori M; Plebani L; Bolla A; Rossi A; Vallone L; Gandolfi A; Tinari C; D'Addio F; Nasr MB; Loretelli C; Scaranna C; Bellante R; Manfrini R; Muratori F; Franzetti I; Orsi E; Gazzaruso C; Ghelardi R; Desenzani P; Genovese S; Girelli A; Folli F; Berra C; Fiorina P
    Pharmacol Res; 2022 Sep; 183():106374. PubMed ID: 35908663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules.
    Kim JH; Ko HY; Wang HJ; Lee H; Yun M; Kang ES
    Diabetes Obes Metab; 2020 Mar; 22(3):373-382. PubMed ID: 31692240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
    Shao SC; Chang KC; Lin SJ; Chang SH; Hung MJ; Chan YY; Lai EC
    Cardiovasc Diabetol; 2021 Oct; 20(1):213. PubMed ID: 34688282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
    Morieri ML; Consoli A; Sesti G; Purrello F; Avogaro A; Fadini GP;
    Diabetes Metab Res Rev; 2021 Jan; 37(1):e3353. PubMed ID: 32453482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism.
    Op den Kamp YJM; Gemmink A; de Ligt M; Dautzenberg B; Kornips E; Jorgensen JA; Schaart G; Esterline R; Pava DA; Hoeks J; Schrauwen-Hinderling VB; Kersten S; Havekes B; Koves TR; Muoio DM; Hesselink MKC; Oscarsson J; Phielix E; Schrauwen P
    Mol Metab; 2022 Dec; 66():101620. PubMed ID: 36280113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
    van Bommel EJM; Herrema H; Davids M; Kramer MHH; Nieuwdorp M; van Raalte DH
    Diabetes Metab; 2020 Apr; 46(2):164-168. PubMed ID: 31816432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin.
    Furuya F; Fujita Y; Matsuo N; Minamino H; Oguri Y; Isomura N; Ikeda K; Takesue K; Li Y; Kondo A; Mano F; Inagaki N
    EBioMedicine; 2022 Dec; 86():104342. PubMed ID: 36423374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
    Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
    PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH
    Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
    Scholtes RA; van Raalte DH; Correa-Rotter R; Toto RD; Heerspink HJL; Cain V; Sjöström CD; Sartipy P; Stefánsson BV
    Diabetes Obes Metab; 2020 Apr; 22(4):549-556. PubMed ID: 31742881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
    Bonner C; Kerr-Conte J; Gmyr V; Queniat G; Moerman E; Thévenet J; Beaucamps C; Delalleau N; Popescu I; Malaisse WJ; Sener A; Deprez B; Abderrahmani A; Staels B; Pattou F
    Nat Med; 2015 May; 21(5):512-7. PubMed ID: 25894829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production.
    Capece U; Pavanello C; Cinti F; Leccisotti L; Mezza T; Ciccarelli G; Moffa S; Di Giuseppe G; Soldovieri L; Brunetti M; Giordano A; Giaccari A; Calabresi L; Ossoli A
    Diabetes Ther; 2024 Jan; 15(1):257-268. PubMed ID: 37883003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A
    Brown E; Wilton MM; Sprung VS; Harrold JA; Halford JCG; Stancak A; Burgess M; Howarth E; Umpleby AM; Kemp GJ; Wilding JP; Cuthbertson DJ
    BMJ Open; 2021 Jul; 11(7):e045663. PubMed ID: 34285005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
    Okada J; Yamada E; Saito T; Yokoo H; Osaki A; Shimoda Y; Ozawa A; Nakajima Y; Pessin JE; Okada S; Yamada M
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
    Fioretto P; Del Prato S; Buse JB; Goldenberg R; Giorgino F; Reyner D; Langkilde AM; Sjöström CD; Sartipy P;
    Diabetes Obes Metab; 2018 Nov; 20(11):2532-2540. PubMed ID: 29888547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.